ImmunityBio’s (IBRX) Biggest Strategic Shift Yet?
Автор: Invest With Olivier
Загружено: 2026-03-03
Просмотров: 427
Описание:
ImmunityBio’s (IBRX) Biggest Strategic Shift Yet?
ImmunityBio (IBRX stock) just secured Saudi approval for ANKTIVA in metastatic non-small cell lung cancer — its first approval outside bladder cancer. For IBRX investors, this signals that ImmunityBio may be evolving from a single-indication story into a broader immune-oncology platform across multiple cancers. If ANKTIVA expands globally and works alongside blockbuster therapies, IBRX stock could be targeting a multi-billion-dollar market opportunity over the coming years.
$IBRX, IBRX, ImmunityBio stock, immunity bio stock, ImmunityBio,
I use Interactive Brokers to buy most of the stocks I talk about. Create an account and get FREE stocks here: https://ibkr.com/referral/olivier574
Disclaimer
This video is for educational and entertainment purposes only and is not investment advice. I am purely documenting my opinions on companies that interest me. I am not a Financial Advisor and I am not your Financial Advisor. You risk losing your money by investing. Please do your own due diligence and get advice from an expert. I am human and get things wrong.
Tags
$IBRX, IBRX, ImmunityBio stock, immunity bio stock, ImmunityBio, biotech stocks, biotech investing, pharma stocks, pharma investing, pharmaceutical stocks, pharmaceutical investing, biotech news, pharma news
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
![🔴 EXPRESS BIEDRZYCKIEJ | MAGDALENA RIGAMONTI, DARIUSZ ĆWIKLAK [NA ŻYWO]](https://imager.clipsaver.ru/ZzqkvKZhVuw/max.jpg)
